European Pharmaceutical Review

OCTOBER 11, 2023

As part of newly acquired assets from live biotherapeutics products (LBP) manufacturer Federation Bio, Kanvas Biosciences now has two active microbiome-based clinical programmes. This acquisition allows us to manufacture and clinically investigate complex microbial consortia much faster than previously envisioned.

Immunity 81

Immunity Immunization 81

European Pharmaceutical Review

OCTOBER 26, 2023

Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months. Clinically meaningful PFS benefit was seen in patients with non-squamous tumours.

Chemotherapy 97

Chemotherapy Drug Development 97

Pharmaceutical Business Review

APRIL 26, 2024

As part of the new collaboration , the two companies will work together to co-c reate the candidate for the oncology target, leveraging PepMetics technology.

59

59

Pharmaceutical Business Review

JANUARY 25, 2024

The site is strategically equipped to advance the clinical development of genetic medicine programmes. Among these is Covigenix, a Covid-19 booster vaccine, and future candidates targeting rare disease, eye and ophthalmic conditions, oncology, and other infectious diseases.

Vaccines 104

Vaccines 104

pharmaphorum

JULY 8, 2021

GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. . billion acquisition of Tesaro, which added PARP inhibitor Zejula (niraparib) and a pipeline of other oncology candidates.

Compounding 104

Compounding 104

pharmaphorum

NOVEMBER 17, 2022

As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important. Healthcare professionals trust MSLs to keep them informed and up-to-date about the latest treatments, especially in fast-moving areas like oncology.

Communication 113

Communication Pharmaceutical Companies Pharmaceutical Companies 113

European Pharmaceutical Review

DECEMBER 12, 2023

Additionally, Morel shares highlights and key clinical data from Innate Pharma’s pipeline and as well as his predictions on where the sector is headed, meanwhile considering the impact of accelerating technological innovations. Innate Pharma is an international clinical-stage biotechnology oncology company based in France.

Immunity 110

Immunity Immunization Chemotherapy Pharmaceutical Companies 110

Pharmacy Times

DECEMBER 16, 2022

Clinical oncology pharmacist Amy Indorf, PharmD, BCOP, discusses her presentation on the role of PARP inhibitors for ovarian cancer.

49

49

European Pharmaceutical Review

NOVEMBER 16, 2023

In the past couple of months, BeiGene has experienced regulatory progress for two of its oncology assets in clinical development. According to Data Bridge Market Research, the haematology /oncology market will value $14.83 According to Data Bridge Market Research, the haematology /oncology market will value $14.83

Immunity 52

Immunity Immunization 52

European Pharmaceutical Review

NOVEMBER 7, 2023

Positive results for a combination treatment using the first Fc-silent investigational monoclonal antibody in pivotal clinical trials that is designed to block and bind to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), have been announced. The treatment is being evaluated in patients with upper GI adenocarcinomas.

Chemotherapy 96

Chemotherapy 96

pharmaphorum

JUNE 1, 2022

For the first time since 2019, the American Society of Clinical Oncology (ASCO) annual meeting will be an in-person conference. We’re excited to re-connect with fellow oncology and clinical care professionals from across the globe to learn from one another and discuss key advances in cancer care and research.

Drug Development 57

Drug Development Hospitals 57

pharmaphorum

MARCH 23, 2022

Merck & Co’s chief medical officer and head of clinical development Dr Roy Baynes has announced his retirement from the company to take up a new role alongside his former colleague Roger Perlmutter at biotech Eikon Therapeutics. billion last year.

Vaccines 98

Vaccines Diabetes 98

European Pharmaceutical Review

JUNE 27, 2023

In April 2023, MaaT Pharma announced that the FDA cleared the Investigational New Drug (IND) application to initiate in the US Phase III pivotal clinical trial evaluating MaaT013 for the treatment of acute graft vs host disease. What are the most promising microbiome therapeutics in clinical development?

Immunity 101

Immunity Immunization Chemotherapy Vaccines 101

Board Vitals - Pharmacist

JANUARY 11, 2024

Since Christie’s or Franklin’s or Pemberton’s eras, the role of the pharmacist has changed. Pharmaceutical industry: Pharmacists may design or conduct clinical drug trials and help to develop new drugs. According to the U.S. Licensing boards for these specialties vary. Or recognize them on social media by using #NationalPharmacistDay.

Retail Drug Stores 98

Retail Drug Stores Hospitals Doctor of Pharmacy Dosage 98

PharmaState Academy

DECEMBER 11, 2023

The potential growth of the Competitive Intelligence landscape in India was emphasized, along with the use of social media analytics, patient advocacy groups, and the monitoring activities of clinical research organizations. They highlighted the importance of clinical trial information and its role in aiding primary research.

Biosimilars 52

Biosimilars 52

European Pharmaceutical Review

FEBRUARY 6, 2023

PKC theta plays a critical role in controlling T cell function and is a key driver of several highly prevalent autoimmune diseases. ” Clinical success begins early for small molecule drugs… The need for sustained, high levels of target inhibition was required to drive efficacy.

Compounding 88

Compounding Immunity Immunization 88

Pharmaceutical Technology

MAY 30, 2023

Genmab AS’s epcoritamab presents as the top European drug launch and only oncological therapy. Moreover, the top three drug launches are set for first release within this region, further underscoring the prominent role of the US market and its profound influence on the pharmaceutical sector. Similarly, Almirall S.A.,

Vaccines 105

Vaccines Drug Development 105

pharmaphorum

FEBRUARY 24, 2022

This enabled rapid recruitment to multiple COVID-19 clinical trials throughout England/UK. . Can data help us to identify where there is high clinical need and/or research low engagement? Stephen Lock is head of business intelligence, NIHR Clinical Research Network. Ed Merivale is therapy relationship manager, oncology at NIHR.

Hospitals 104

Hospitals 104

European Pharmaceutical Review

APRIL 12, 2023

In November 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) Innovation Passport was awarded to Boehringer Ingelheim’s investigational BI 907828 in de-differentiated liposarcoma (DDLPS), a rare and aggressive oncology indication for which there has been no new first-line treatment in over forty years.

Immunity 87

Immunity Immunization Drug Development 87

European Pharmaceutical Review

JANUARY 9, 2024

TALZENNA the first and only PARP inhibitor licensed in the EU for use with XTANDI for patients with mCRPC, with or without gene mutations” The treatment is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) in individuals where chemotherapy is not clinically indicated.

Chemotherapy 87

Chemotherapy 87

Pharmaceutical Business Review

JANUARY 31, 2024

NT-I7 (efineptakin alfa) is claimed to be the only clinical-stage long-acting human IL-7.

Immunity 59

Immunity Immunization Vaccines 59

pharmaphorum

OCTOBER 17, 2022

Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed. Marie-Louise Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development.

Immunity 113

Immunity Immunization Drug Development 113

Amber

FEBRUARY 19, 2024

Ringena brings a wealth of experience from her roles at Vivid Clear Rx and Hy-Vee, where she excelled at applying technology to enhance health care outcomes. The provider specializes in transplant, infusion and specialty care, including rare/orphan drugs and oncology.

Specialty Pharmacies 52

Specialty Pharmacies 52

European Pharmaceutical Review

APRIL 3, 2023

These results have led to a major amendment in a European Phase III paediatric clinical trial. The oncology treatment showed clinical activity across patients of all ages with the three neuroblastoma-specific hotspot ALK mutations. In 2008, the ALK gene was found to hold a key role in the disease.

Chemotherapy 79

Chemotherapy Hospitals 79

pharmaphorum

JANUARY 7, 2022

As chief medical officer, head of global medical affairs, patient safety and patient affairs – putting patient interests first is central to my role and values. Quality of life-specific endpoints need to be a permanent component of future clinical trial protocols. I often ask myself where the next leap in patient care will come from.

104

104

pharmaphorum

SEPTEMBER 8, 2021

The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular focus on oncology. The post Biotech Insight podcast: Overcoming planning challenges in oncology appeared first on.

52

52

Pharmaceutical Business Review

JANUARY 31, 2024

NT-I7 (efineptakin alfa) is claimed to be the only clinical-stage long-acting human IL-7.

Immunity 52

Immunity Immunization Vaccines 52

pharmaphorum

JULY 23, 2021

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the field becomes more crowded, digital tools may be critical for improving outcomes, says a new whitepaper.

52

52

pharmaphorum

FEBRUARY 21, 2022

The clinical research industry has long struggled with participant diversity. One study found that only 5% of Black or Asian United Kingdom residents had ever participated in a clinical trial. With many patients unable to travel, clinical trial sites initiated more remote, flexible, and hybrid trials than ever before.

Vaccines 109

Vaccines Physician Offices Hospitals 109

pharmaphorum

APRIL 19, 2022

It has long been understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. Together, we will unite to learn, debate, and discuss; leverage the therapeutic opportunity of this pathway; and critically address the huge unmet clinical need. Download the full event guide here.

Drug Development 52

Drug Development 52

pharmaphorum

JUNE 8, 2021

Speaking to us after his appearance on the Withers podcast Talking Success , Mei says he founded Antengene – after leading oncology drug development at J&J, Novartis and Celgene– to address this need for innovative drugs with best-in-class and/or first-in-class potential targeting medical needs specific to APAC. Unmet needs in cancer.

Chemotherapy 104

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 104

European Pharmaceutical Review

DECEMBER 30, 2023

Oncology continued to dominate the dealmaking in terms of therapeutic area, most notably antibody-drug conjugates (ADCs), which were the key asset in three major deals,” he adds. Strategic partnerships and alliances will continue to play critical roles in early-stage R&D.” What modalities will dominate biopharma dealmaking in 2024?

Drug Development 104

Drug Development 104

pharmaphorum

JULY 20, 2021

Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief medical officer Bill Grossman to a new role as its head of oncology clinical research. Bill Grossman.

52

52

pharmaphorum

NOVEMBER 15, 2022

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. The post Lantheus on POINT in radio-oncology with $2bn licensing deal appeared first on.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is formulated as tablets for oral route of administration.

Chemotherapy 40

Chemotherapy Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is formulated as tablets for oral route of administration.

Chemotherapy 40

Chemotherapy Drug Development 40

pharmaphorum

MAY 27, 2022

With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized.

Immunity 52

Immunity Immunization 52